Author Index Volume 26 (2014)

The issue number is given in front of the page numbers

Acheampong, F., B.P. Anto and G.A. Koffuor, Medication safety strategies in hospitals – A systematic review


Anto, B.P., see Acheampong, F.

Bakhsh, H.T., S.J. Perona, W.A. Shields, S. Salek, A.B. Sanders and A.E. Patanwala, Medication errors in psychiatric patients boarded in the emergency department


Bavdekar, S.B., see Bang, V.

Brookwell, L., C. Hogan, D. Healy and D. Mangin, Ninety-three cases of alcohol dependence following SSRI treatment

Card, A.J., M.C.E. Simsekler, M. Clark, J.R. Ward and P.J. Clarkson, Use of the Generating Options for Active Risk Control (GO-ARC) Technique can lead to more robust risk control options

Chopra, D., see Rehan, H.S.

Clark, M., see Card, A.J.

Clarkson, P.J., see Card, A.J.

Clarkson, P.J., see Horberry, T.

Curreen, M. and J. Lidmila, Zopiclone: Is there cause for concern in addiction services and general practice?

da Silva Dal Pizzol, T., see Maggi, C.B.

de Boer, A., see Warnier, M.J.

De Bruin, M.L., see Warnier, M.J.

Enoki, H., see Katahira, K.

Fontugne, E.A., The Affordable Care Act: Opportunities for collaboration between doctors and lawyers

Gharaei, A.G., see Afifi, S.

Gogtay, N.J., see Bang, V.

Greech, V., Births and male:female birth ratio in Scandinavia and the United Kingdom after the Windscale fire of October 1957

Griebeler, I.H., see Maggi, C.B.
Healy, D., G. Howe, D. Mangin and J.L. Noury, Sudden cardiac death & The Reverse Dodo Verdict (2) 71–79
Healy, D., see Brookwell, L. (2) 99–107
Healy, D., see Hogan, C. (2) 109–116
Herxheimer, A., see Menkes, D.B. (3) 163–170
Hoes, A.W., see Warnier, M.J. (2) 89–98
Hogan, C., J.L. Noury, D. Healy and D. Mangin, One hundred and twenty cases of enduring sexual dysfunction following treatment (2) 109–116
Hogan, C., see Brookwell, L. (2) 99–107
Holani, S.N., see Rehan, H.S. (1) 1–8
Holtkamp, F.A., see Warnier, M.J. (2) 89–98
Horberry, T., Y.-C. Teng, J. Ward, V. Patil and P.J. Clarkson, Guidewire retention following central venous catheterisation: A human factors and safe design investigation (1) 23–37
Howe, G., see Healy, D. (2) 71–79
Izaham, A., see Mat, W.R.W. (2) 57–60
Jaber, L., Preventive intervention for iron deficiency anaemia in a high risk population (3) 155–162
Jahani, P., see Afifi, S. (3) 139–145
Kannan, S., see Bang, V. (2) 61–70
Koffuer, G.A., see Acheampong, F. (3) 117–131
Lankarani, K.B., see Afifi, S. (3) 139–145
Lexchin, J. and B. Mintzes, A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation (4) 213–225
Lidmila, J., see Curreen, M. (4) 183–189
Maggi, C.B., I.H. Griebeler and T. da Silva Dal Pizzol, Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors (1) 9–22
Maharloui, N., see Afifi, S. (3) 139–145
Mallad, A., see Bang, V. (2) 61–70
Manap, N.A., see Mat, W.R.W. (2) 57–60
Mangin, D., see Brookwell, L. (2) 99–107
Mangin, D., see Healy, D. (2) 71–79
Mangin, D., see Hogan, C. (2) 109–116
Mat, W.R.W., N. Yahya, A. Izaham, R.A. Rahman, N.A. Manap and J.M. Zain, Near fatal error in management of postoperative epidural analgesia (2) 57–60
Menkes, D.B. and A. Herxheimer, Interaction between antidepressants and alcohol: Signal amplification by multiple case reports (3) 163–170
Mintzes, B., see Lexchin, J. (4) 213–225
Mishra, R., see Rehan, H.S. (1) 1–8
Mol, P.G.M., see Warnier, M.J. (2) 89–98
Namazi, S., see Afifi, S. (3) 139–145
Noury, J.L., see Healy, D. (2) 71–79
Noury, J.L., see Hogan, C. (2) 109–116
Patanwala, A.E., see Bakhsh, H.T. (4) 191–198
Patil, V., see Horberry, T. (1) 23–37
Perona, S.J., see Bakhsh, H.T. (4) 191–198
Persaud, N., see Shoucri, R. (3) 147–153
Peymani, P., see Afifi, S. (3) 139–145
Pikkel, D., A. Sharabi-Nov and J. Pikkel, The importance of side marking in preventing surgical site errors (3) 133–138
Pikkel, J., see Pikkel, D. (3) 133–138
Rahman, R.A., see Mat, W.R.W. (2) 57–60
Rehan, H.S., D. Chopra, S.N. Holani and R. Mishra, An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals (1) 1–8
Rutten, F.H., see Warnier, M.J. (2) 89–98
Salek, S., see Bakhsh, H.T. (4) 191–198
Sanders, A.B., see Bakhsh, H.T. (4) 191–198
Sharabi-Nov, A., see Pikkel, D. (3) 133–138
Shields, W.A., see Bakhsh, H.T. (4) 191–198
Shoucri, R. and N. Persaud, Investigating pharmaceutical marketing in Canada using American prosecutions (3) 147–153
Simsekler, M.C.E., see Card, A.J. (4) 199–211
Teng, Y.-C., see Horberry, T. (1) 23–37
Teraoka, A., see Katahira, K. (4) 227–233
Thatte, U.M., see Bang, V. (2) 61–70
Tsuchiya, Y., see Katahira, K. (4) 227–233
Ward, J., see Horberry, T. (1) 23–37
Ward, J.R., see Card, A.J. (4) 199–211
Warnier, M.J., F.A. Holtkamp, F.H. Rutten, A.W. Hoes, A. de Boer, P.G.M. Mol and M.L. De Bruin, Quality of drug label information on QT interval prolongation (2) 89–98
Yahya, N., see Mat, W.R.W. (2) 57–60
Yoshikawa, T., see Katahira, K. (4) 227–233
Yudina, E.V. and L.E. Ziganshina, Palivizumab and respiratory syncytial virus disease: Selling sickness for future? (1) 39–43
Zain, J.M., see Mat, W.R.W. (2) 57–60
Ziganshina, L.E., see Yudina, E.V. (1) 39–43